化疗药物治疗双原发肿瘤继发急性白血病1例及文献复习

杨喜晶; 周福平; 张迁; 钱其军

doi:10.3969/j.issn.1006-0111.2015.05.020

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

化疗药物治疗双原发肿瘤继发急性白血病1例及文献复习

杨喜晶, 周福平, 张迁, 钱其军

文章导航 > 药学实践与服务 > 2015 > 33(5): 453-456

杨喜晶, 周福平, 张迁, 钱其军. 化疗药物治疗双原发肿瘤继发急性白血病1例及文献复习[J]. 药学实践与服务, 2015, 33(5): 453-456. doi: 10.3969/j.issn.1006-0111.2015.05.020

引用本文:

YANG Xijing, ZHOU Fuping, ZHANG Qian, QIAN Qijun. One case of double primary tumors with secondary acute leukemia induced by chemotherapy drugs and literature review[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 453-456. doi: 10.3969/j.issn.1006-0111.2015.05.020

Citation:

YANG Xijing, ZHOU Fuping, ZHANG Qian, QIAN Qijun. One case of double primary tumors with secondary acute leukemia induced by chemotherapy drugs and literature review[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 453-456. doi: 10.3969/j.issn.1006-0111.2015.05.020

化疗药物治疗双原发肿瘤继发急性白血病1例及文献复习

doi: 10.3969/j.issn.1006-0111.2015.05.020

东方肝胆外科医院肿瘤生物治疗科, 上海 200438

One case of double primary tumors with secondary acute leukemia induced by chemotherapy drugs and literature review

Department of Biotherapy, Eastern Hepatobiliary Surgical Hospital, Shanghai 200438, China

摘要: 近年来,随着化疗的大量开展,继发性白血病发病率逐年升高,笔者报道1例卵巢癌并发乳腺癌患者经化疗、放疗后出现急性粒-单细胞白血病,从初次化疗至诊断急性白血病的时间为37个月,起病急、生存期短。文献报道烷化剂、拓扑异构酶I抑制剂、铂类均易诱发继发性白血病。造血干细胞移植可降低病死率、延长无进展生存期。
- 继发性白血病 /
- 卵巢癌 /
- 乳腺癌 /
- 化疗
Abstract: In recent years, with a large number of chemotherapy development, the incidence of secondary leukemia increased year by year,an acute myelomonocytic leukemia after chemotherapy and radiotherapy in 1 case of ovarian cancer and breast cancer was reported. The time from first chemotherapy to acute leukemia onset was 37 months. This patient had rapid onset and short survival period. Reports in the literature suggested that alkylating agents, topoisomerase I inhibitors, platinum were all easy to induce secondary leukemia. Hematopoietic stem cell transplantation coud reduce mortality and prolong progression free survival.
- secondary leukemia /
- ovarian cancer /
- breast cancer /
- chemotherapy

[1]	Smit CG, Meyler L.Acute myeloid leukaemia after treatment with cytostatic agents[J]. Lancet, 1970, 2(7674):671-672.
[2]	Leone G,Voso MT,Sica S, et al, Therapy related leukemias: susceptibility, prevention and treatment[J]. Leuk Lymphoma, 2001,41 (3-4): 255-276.
[3]	肖志坚,都玉书.继发性白血病的研究现况[J].中华血液学杂志,2001,22(11):613-616.
[4]	Markman M. Chronic myelocytic leukemia as a secondary malignant condition in a patient receiving prolonged chemotherapy for ovarian carcinoma[J]. West J Med,1985,143 (2): 243.
[5]	Atichartakarn V, Punyammalee B, Nitiyanant P. Therapy related acute non-lymphocytic leukemia: report of 4 cases[J].Southeast Asian J Trop Med Public Health,1985, 16(3):421-430.
[6]	夏忠军.卵巢癌化疗的继发性白血病[J].国际内科学杂志,1991,2(3):22-24.
[7]	Chambers SK, Chopyk RL, Chambers JT, et al, Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer[J]. Cancer, 1989,64 (12): 2459-2461.
[8]	Yokoyama Y, Futagami M, Fukushi Y, et al, Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin and cyclophosphamide for stage IV epithelial ovarian cancer[J]. Arch Gynecol Obstet,2000,263 (4): 206-207.
[9]	Travis LB, Holowaty EJ, Bergfeldt K, et al, Risk of leukemia after platinum-based chemotherapy for ovarian cancer[J]. N Engl J Med, 1999,340 (5): 351-357.
[10]	Yeasmin S, Nakayama K, Ishibashi M, et al, Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel-and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review[J]. Int J Gynecol Cancer, 2008,18 (6): 1371-1376.
[11]	Ishikawa M, Nakayama K, Rahman MT, et al, Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemotherapy (paclitaxel and carboplatin) and radiation therapy in ovarian cancer: a case report[J]. Eur J Gynaecol Oncol,2014,35 (4): 443-448.
[12]	Vay A, Kumar S, Seward S, et al, Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis[J]. Gynecol Oncol,2011,123 (3): 456-460.

[1]	夏晶, 陈行, 陈建明, 武鑫. 冰片辅助胶质瘤治疗的临床前研究进展 . 药学实践与服务, 2023, 41(4): 202-206. doi: 10.12206/j.issn.2097-2024.202203126
[2]	张敏, 汪晓河, 周阳云, 石美智, 韩忻云, 韩向晖, 陈君君. 基于网络药理学和分子对接的苦参抗乳腺癌潜在机制研究 . 药学实践与服务, 2023, 41(12): 722-732. doi: 10.12206/j.issn.2097-2024.202302001
[3]	马小雨, 罗彩萍, 刘悦. 代谢组学在乳腺癌诊疗中应用的研究进展 . 药学实践与服务, 2023, 41(3): 139-145. doi: 10.12206/j.issn.2097-2024.202109112
[4]	雷碧黠, 张梦瑶, 陈晓锐, 梁蓓蓓, 解伟, 王华菁, 李博华. 表没食子儿茶素没食子酸酯联合曲妥珠单抗对HER2过表达乳腺癌细胞增殖的影响及其机制 . 药学实践与服务, 2022, 40(2): 136-142. doi: 10.12206/j.issn.1006-0111.202112035
[5]	周菊香, 王双英, 佘建涛, 曾贤良, 张继红. 肾衰竭对乳腺癌患者多西他赛暴露和不良反应的影响 . 药学实践与服务, 2022, 40(6): 571-575. doi: 10.12206/j.issn.2097-2024.202203068
[6]	王玮婷, 殷雪琴, 夏金娥, 张夏炎. 五味子乙素通过ROS介导内质网应激诱导人乳腺癌MDA-MB-231细胞凋亡的研究 . 药学实践与服务, 2021, 39(6): 499-503, 533. doi: 10.12206/j.issn.1006-0111.202106123
[7]	陈炳辰, 于恩达. 增强紫杉醇对结直肠癌化疗疗效的研究进展 . 药学实践与服务, 2020, 38(6): 501-505. doi: 10.12206/j.issn.1006-0111.202007031
[8]	周瑾, 李盛建, 覃福礼, 杨新颖, 张晓琳, 赵亮. 月腺大戟素A通过干扰PKD1介导的MEK/ERK和PI3K/AKT信号通路抑制乳腺癌细胞增殖的研究 . 药学实践与服务, 2020, 38(3): 241-244, 276. doi: 10.12206/j.issn.1006-0111.201912008
[9]	曹青青, 李盛建, 李云青, 葛继云, 陈俊, 周瑾, 钱跹, 赵亮. 月腺大戟的化学成分及其乳腺癌细胞毒活性研究 . 药学实践与服务, 2019, 37(4): 309-313,317. doi: 10.3969/j.issn.1006-0111.2019.04.005
[10]	唐杰, 林厚文, 孙凡. 海绵来源的smenospongine诱导乳腺癌MCF7细胞凋亡机制研究 . 药学实践与服务, 2018, 36(5): 399-402,421. doi: 10.3969/j.issn.1006-0111.2018.05.004
[11]	靳海潮, 邢方凯, 陈涛, 吕文苓. 氨柔比星用于小细胞肺癌二线治疗的荟萃分析 . 药学实践与服务, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
[12]	齐婧. 阿瑞匹坦对乳腺癌AC方案化疗后中重度呕吐患者的二级预防 . 药学实践与服务, 2017, 35(2): 158-160,181. doi: 10.3969/j.issn.1006-0111.2017.02.015
[13]	唐跃年, 金樑, 孙朝荣. 治疗遗传性卵巢癌的新药——奥拉帕尼 . 药学实践与服务, 2015, 33(4): 373-375. doi: 10.3969/j.issn.1006-0111.2015.04.022
[14]	何志高, 严俊, 陈国涵, 鲍思蔚, 翟晓波, 金丽, 施燕. 长春瑞滨(NP)或吉西他滨(GP)联合顺铂治疗晚期非小细胞肺癌的成本效用研究 . 药学实践与服务, 2012, 30(6): 462-463,480. doi: 10.3969/j.issn.1006-0111.2012.06.020
[15]	黄景彬, 钟延强. 乳腺癌靶向治疗的新策略 . 药学实践与服务, 2011, 29(5): 324-327.
[16]	王晶, 赵娜萍, 舒丽芯, 刘斌, 张婉露, 严天虹, 潘勇华, 张黎. 参麦注射液联合TE化疗方案治疗进展期乳腺癌的临床观察研究 . 药学实践与服务, 2011, 29(3): 184-187,203.
[17]	孙德好, 邵凌, 刘胜, 陈森林, 曹晓冰. 依立替康/氟尿嘧啶/亚叶酸三药联用治疗晚期胃癌的临床疗效观察 . 药学实践与服务, 2009, 27(3): 189-192.
[18]	刘懿萱, 章琎, 陈盛新, 李捷玮. 三种化疗方案治疗进展期胃癌的成本效果分析 . 药学实践与服务, 2007, (2): 117-120.
[19]	赵强, 常英, 潘靖, 张军东. 云硒冲剂对乳腺癌术后化疗患者免疫功能的影响 . 药学实践与服务, 2004, (3): 156-157.
[20]	朱全刚, 魏水易. 抗肿瘤新药紫杉醇 . 药学实践与服务, 1995, (1): 12-14.

点击查看大图

计量

文章访问数: 2939
HTML全文浏览量: 215
PDF下载量: 461
被引次数: 0

化疗药物治疗双原发肿瘤继发急性白血病1例及文献复习

doi: 10.3969/j.issn.1006-0111.2015.05.020

东方肝胆外科医院肿瘤生物治疗科, 上海 200438

收稿日期: 2015-01-12
修回日期: 2015-04-28

关键词:

继发性白血病 /

卵巢癌 /

乳腺癌 /

化疗

摘要: 近年来,随着化疗的大量开展,继发性白血病发病率逐年升高,笔者报道1例卵巢癌并发乳腺癌患者经化疗、放疗后出现急性粒-单细胞白血病,从初次化疗至诊断急性白血病的时间为37个月,起病急、生存期短。文献报道烷化剂、拓扑异构酶I抑制剂、铂类均易诱发继发性白血病。造血干细胞移植可降低病死率、延长无进展生存期。